(1 - 15 from 19
)
ESMO 2017: Rucaparib Shows Clinical Benefit as Maintenance ...
www.esmo.org
Jonathan Ledermann, Professor of Medical Oncology at UCL Cancer Institute and UCL Hospitals, London, UK presented findings from the double-blind, multinational phase III ARIEL3 trial (NCT ), which tested rucaparib as a maintenance therapy compared to placebo in women with high-grade ovarian, fallopian tube, or primary peritoneal cancer ...
Artios Pharma Announces Appointment of Dr. Ian PR Newswire UK
www.prnewswire.co.uk
Jonathan Ledermann is Professor of Medical Oncology in the UCL Cancer Institute and Director of Cancer Research UK and UCL Cancer ...
Olaparib confers ‘unprecedented’ PFS benefit in ovarian cancer
www.healio.com
Jonathan Ledermann, BSc, MD, FRCP; UCL Cancer InstituteUCL Clinical Trials CentreCancer Research UK. Disclosures: Ledermann reports ...
sorted by relevance / date